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Abstract: Three known impurities in oseltamivir phosphate bulk drug at level 
0.1% (ranging from 0.05-0.1%) were detected by gradient reverse phase high 
performance liquid chromatography. These impurities were preliminarily 
identified by the mass number of the impurities. Different experiments were 
conducted and finally the known impurities were synthesized and 
characterized.    
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Introduction  
Oseltamivir is an ester prodrug, which is rapidly and extensively hydrolysed in vivo to its 
active metabolite oseltamivir carboxylate, a potent and selective inhibitor of influenza virus 
neuraminidase
1
 is considered the leading currently available antiviral to counter a serious 
epidemic or pandemic outbreak of influenza
2,3
. The current concerns over avian influenza A 
(H5N1) have created an increased demand for this drug. Pharmaceutical counterfeiting is a 
well recognized global health problem with a particular impact in developing countries 
where drug-regulatory systems are weak or ineffective
4
. There have been many alarming 
reports lasting recent years of counterfeit antimalarials, antibiotics, hormones and steroids, 
analgesics and antipyretics, anti-asthma and anti-allergy drugs
5-11
.  
 Oseltamivir phosphate is a white crystalline solid with the chemical name (3R,4R,5S)-
4-acetylamino-5-amino-3(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid, ethyl ester, 
phosphate (1:1). The chemical formula is C16H28N2O4 (free base). The molecular weight of 
oseltamivir is 312.4 and 410.4 for oseltamivir phosphate salt
12
. The structural formula is as 
follows: 
















 There are several process impurities/related substances associated with the manufacture 
of oseltamivir phosphate. Different process related impurities have been observed with 
various synthetic routes and/or manufacturing processes. Six of the known oseltamivir 
phosphate related substances have been mentioned in International Pharmacopoeia. All these 
impurities are never present together while we are preparing bulk drug or preparing 
formulation. 
 The International Pharmacopoeia
12
 specifies that individual impurity is not more than 
0.1% and total impurity is not more than 0.7%. During the process development of 
oseltamivir phosphate three known impurities were identified in the analysis of different 
batches whose percent area ranged from 0.05-0.1% by HPLC
12
. A comprehensive study has 
been carried out to isolate or to prepare and characterize these impurities. To the best of our 
knowledge, synthesis rout of impurities is novel and not reported in literature. Due to the 
importance of regulatory authorities
13
 all the impurities which are at the level of >0.1% must 
be identified and characterized.  
 A literature search revealed that only analytical procedure
14-18
 is available but nobody has 
reported synthesis, isolation and characterization of impurities in the purified form starting 
from oseltamivir phosphate. The present communication involves the isolation or preparation 




The investigated samples of bulk oseltamivir phosphate were received from pharmasolve 
specialities (I) Pvt. Ltd. Mumbai. 
High performance liquid chromatography (HPLC)   
An LC method was used for monitoring the reaction of oseltamivir impurities. A shimadzu 
model LC2010CHT equipped with a UV detector was used. The chromatographic conditions 
optimized were ODS, 50×4.6 mm, 3 µ column with a mobile phase -A consisting  900:100(v/v) 
of 0.05 M KH2PO4 buffer pH 6.0 and acetonitrile and mobile phase-B consisting 
100:900(v/v) of 0.05 M KH2PO4 buffer pH 6.0 and acetonitrile with a timed gradient 
programme of T/% B:0/20,3/50, 8/100, 15/100, 16/20, 20/20. Detection was carried out at 
220 nm and the flow rate 1.5 mL/min. Data was recorded by using LC solutions software. 
High performance liquid chromatography (preparative) 
An inhouse LC method was developed for the isolation of oseltamivir impurities. A waters 
LC controller equipped with a UV detector was used. The Prep-HPLC method uses a C18 
column (YMC Pack Pro.C-18,250 mm
*
 20 mmi.d., 10 um particle size) with a mobile phase 
A consisting of 0.02 M ammonium acetate and  mobile phase B consisting acetonitrile timed 
gradient programme of T/%B: 0/0, 5/0, 8/80, 15/80, 16/0, 20/0. Detection was carried out at 
207 nm and the flow rate was 15.0 mL/min. Data was recorded by using Empower software. 
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Mass spectrometry 
Electrospray ionization mass spectroscopy was performed using an ion trap mass 
spectrometer (Model 6310 agilent). The positive and negative electrospray MS data was 
obtained by switching the capillary voltage between n+ 5000 and -4500V respectively.  
NMR spectroscopy 
The NMR experiments were performed on Bruker avance II 400 MHz. The 1H chemical shift 
values were reported on the δ scale in ppm, relative to TMS (δ=0.00) and the 
13
C chemical 





C experiment was run using a mixing time of 1000 ns. 
FT-IR spectroscopy 
The IR spectra were recorded in the solid state as KBr dispersion medium using Perkin 
Elmer spectrum 100 FT-IR spectrophotometer. 
Synthesis of impurities 
Synthesis if impurity 1 and 2 
Oseltamivir base (1 g) was charged with 100 mL methanol into a double necked round 
bottom flask with magnetic stirrer. Methanolic sodium hydroxide was added drop wise and 
the reaction mass was heated very carefully and the reaction mass was refluxed at methanol 
boiling point. The reaction was monitored after every 1 h by HPLC. After completion of 
reaction the reaction mass was neutralised with dilute HCl. The HPLC analysis shown 2 
peaks separately which confirm the presence of two different impurities. Both peaks were 
purified using preparative HPLC and marked as fraction-1 and 2 (Scheme 1). The salt was 











































Impurity-2(B)  Scheme 1. Synthesis if impurity 1 and 2 
 
116 Y. K. SHARMA et al. 
 
Synthesis of impurity 3 
Oseltaivir base (1 g) was charged with 100 mL methanol into a double necked round bottom 
flask with megnatic stirrer. To this methanolic sodium hydroxide was added and the reaction 
mass was stirred at room temperature. The reaction was monitored after every 1 h by HPLC. 
The HPLC analysis had shown 1 peak which confirms the presence of one different 
impurity. This peak was purified using preparative HPLC and marked as fraction-3 (Scheme 2). 
After completion of reaction the reaction mass was neutralised with dilute HCl. The salt was 































Oseltamivir Impurity-3(D)  
Scheme 2. Synthesis if impurity 3 
Results and Discussion 
Structure elucidation of impurity 1(Impurity-A) 
Sample was analyzed by HPLC and its purity was found to be 94.13%, molecular weight of 
oseltamivir phosphate impurity-A is 284.36,28 mass unit less than that of oseltamivir 
phosphate. The ESI mass spectrum of  sample gave a protonated molecular ion at m/z 285.1, 
which is the same as oseltamivir phosphate impurity-A, IR spectrum displayed characteristic 
absorptions at 3430.01 & 2968.79,2939.87 cm
-1
 corresponding to >NH and aliphatic >CH 
stretching. The peaks at 1642.69 & 1200.32 cm
-1
 in IR spectrum are indicative of  >C=O 
stretching & O-C stretching, 
1
H signals showed the absence of signals at 4.11-4.19 &         
1.20-1.24 ppm was observed  as multiplet & triplet, which could be attributed to a ethyl 
group absent  in impurity-A, but a significant change observed in the position of 1C & 5C 
protons which is due to change double bond  position in impurity-A, 
13
C signals showed 
absence of signals at 60.52 & 14.02 ppm, which could be attributed to a ethyl group absent in 
impurity-A, but a significant change observed in the position of 1C & 5C carbons which is 
due to change double bond  position in impurity-A. HPLC purity 94.13%, mass +ve m/z 
285.1 (Table 1), IR (KBr): 3430.01, 2968.79,2939.87, 1642.69 & 1200.32 (Table 1); 
1
H 
NMR: 2.03-2.69 (dd,2H), 3.30 (s,1H), 3.54-3.56 (d,1H), 3.95 (m
*
,1H), 6.30 (s,1H), 8.11        
(s, 1H), 1.84 (s, 3H), 2.91 (s,1H), 1.39 (s,4H), 0.78-0.83 (d,6H) (Scheme 3, Table 2); 
13
C 
NMR: 32.72, 75.85, 55.55, 49.70, 134.94, 131.19, 169.97, 23.09, 80.58, 25.11, 25.74, 8.91, 
9.46 (Scheme 4, Table 3). 
Structure elucidation of impurity 2(Impurity-B) 
Sample was analyzed by HPLC and its purity was found to be 92.61%, molecular weight of 
oseltamivir phosphate impurity-B is 284.36,28 mass unit less than that of oseltamivir 
phosphate. The ESI mass spectrum of  sample gave a protonated molecular ion at m/z 285.0, 
which is the same as oseltamivir phosphate impurity-B, IR spectrum displayed characteristic 
absorptions at 3419.69 & 2967.75,2939.35 cm
-1
 corresponding to >NH and aliphatic >CH 
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stretching. The peaks at 1646.68 & 1200.14 cm
-1
 in IR spectrum are indicative of >C=O 
stretching & O-C stretching, 
1
H signals showed the absence of signals at 4.11-4.19 & 
1.20-1.24 ppm was observed as multiplet & triplet, which could be attributed to a ethyl group 
absent in Impurity-B, 
13
C signals showed absence of signals at 60.52&14.02 ppm, which could 
be attributed to a ethyl group absent in Impurity-B. HPLC purity 92.61%, mass +ve m/z 
285.0 (Table 1), IR (KBr): 3419.69, 2967.75,2939.35, 1646.68 & 1200.14 (Table 1); 
1
H NMR: 
6.19 (s, 1H), 3.38 (s, 1H), 3.83-3.85 (d,1H), 3.34-3.36 (m,1H), 2.53-2.60 (dd,2H), 1.83        
(s, 3H), 3.26-3.29 (m,1H), 1.33-1.42 (m, 4H), 0.76-0.85 (m, 6H) (Scheme 3,Table 2); 
13
C 
NMR: 137.41, 76.46, 57.97, 50.35, 35.38, 129.20, 169.49, 170.98, 22.99, 80.26, 25.19, 
25.82, 8.97, 9.51 (Scheme 4, Table 3). 
Table 1. IR and mass spectral data of impurities 1, 2 & 3 





2968.79,2939.87 (aliphatic >CH stretching) 
1642.69 & 1200.32 (>C=O & O-C stretching) 
 
+ve m/z 285.1 
 
2 Impurity-2 
3419.69  (>N-H) 
2967.75,2939.35 (aliphatic >CH stretching) 
1646.68 & 1200.14 (>C=O & O-C stretching) 
 




2966.54,2939.46 (aliphatic >CH stretching) 
1648.06, 1249.80 (>C=O & O-C stretching) 
 





















































































H NMR assignment of impurities 1,2 & 3 
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Structure elucidation of impurity 3(Impurity-D) 
Sample was analyzed by HPLC and its purity was found to be 97.37%, molecular weight 
of oseltamivir phosphate impurity-D is 298.39,14 mass unit less than that of oseltamivir 
phosphate. The ESI mass spectrum of sample gave a protonated molecular ion at m/z 
299.1, which is the same as oseltamivir phosphate impurity-D, IR spectrum displayed 
characteristic absorptions at 3434.02 & 2966.54,2939.46 cm
-1
 corresponding to >NH and 
aliphatic >CH stretching. The peaks at 1648.06 & 1249.80 cm
-1
 in IR spectrum are 
indicative of  >C=O stretching & O-C stretching, 
1
H signals showed the absence of signals 
at 4.11-4.19 & 1.20-1.24 ppm was observed as multiplet & triplet, which could be 
attributed to a ethyl group absent in impurity-D, but an singlet observed at 3.70 ppm  
which could be attributed to a methoxy group present  in Impurity-D, 
13
C signals showed 
absence of signals at 60.52 & 14.02 ppm, which could be attributed to a ethyl group 
absent in Impurity-D, there was a new 
13
C signal at 48.95 ppm was observed which could 
be attributed to a methoxy group present in impurity-D. HPLC purity 97.37%, mass +ve 
m/z 299.1 (Table 1), IR (KBr): 3434.02, 2966.54,2939.46, 1648.06, 1249.80 (Table 1); 
1
H NMR: 6.65 (s, 1H), 3.63-3.68 (m, 1H), 4.15-4.17 (m,1H), 3.37-3.40 (m,1H), 2.21-2.78 
(dd, 2H), 8.16-8.18 (d, 1H), 1.87 (s, 3H), 5.49 (b, 2H), 3.70 (s, 3H), 3.09-3.16 (m,1H),  
1.34-1.48 (m, 4H), 0.76-0.85 (m, 6H) (Scheme 3, Table 2); 
13
C NMR: 138.60, 74.37, 
53.74, 51.97, 29.87, 127.35, 170.28, 165.80, 23.19, 81.01, 24.97, 25.58, 8.88, 9.42, 48.95 






















































































C NMR assignment of impurities 1,2 & 3 
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Table 2. 
1
H NMR spectral data of impurities 1, 2 & 3 
Impurity 1 Impurity 2 Impurity 3 
S.No. 
δ, ppm H δ, ppm H δ, ppm H 
1 2.03-2.69 2H 6.19 1H 6.65 1H 
2 3.30 1H 3.38 1H 3.63-3.68 1H 
3 3.54-3.56 1H 3.83-3.85 1H 4.15-4.17 1H 
4 3.95 1H 3.34-3.36 1H 3.37-3.40 1H 
5 6.30 1H 2.53-2.60 2H 2.21-2.78 2H 
6 8.11 1H   8.16-8.18 1H 
7 1.84 3H 1.83 3H 1.87 3H 
8     5.49 2H 
9     3.70 3H 
10 2.91 1H 3.26-3.29 1H 3.09-3.16         1H 
11,11̍ 1.39 4H 1.33-1.42 4H 1.34-1.48 4H 
12,12̍ 0.78-0.83 6H 0.76-0.85 6H 0.76-0.85 6H 
Table 3. 
13
C NMR spectral data of impurities 1, 2 & 3 
Carbon assignment Impurity 1 Impurity 2 Impurity 3 
  δ, in ppm  
1 32.72 137.41 138.60 
2 75.85 76.46 74.37 
3 55.55 57.97 53.74 
4 49.70 50.35 51.97 
5 134.94 35.38 29.87 
6 131.19 129.20 127.35 
7 169.97 169.49 170.28 
8 169.97 170.98 165.80 
9 23.09 22.99 23.19 
10 80.58 80.26 81.01 
1111̍ 25.1125.74 25.1925.82 24.9725.58 
1212' 8.919.46 8.979.51 8.889.42 
13   48.95 
Conclusion 
This research paper describes the synthesis, isolation and structure elucidation of process 
related impurities in oseltamivir phosphate. The impurities was separated by reverse phase 
chromatographic technique, further isolated these impurities by semi preparative liquid 
chromatography. The isolated impurities was characterized using spectroscopic techniques. 
This isolated impurities was used for mass balance of oseltamivir phosphate technical 
material. The synthesis of impurities was also discussed in brief. 
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